Bioventus Inc. (BVS)
Bioventus Inc. (BVS) Stock Price, Analysis & Data
| Bid | 10.15 |
| Market Cap | 1.2B |
| Revenue (ttm) | 581.85M |
| Net Income (ttm) | 54.46M |
| Beta | 0.65 |
| EPS (ttm) | 0.78 |
| PE Ratio (ttm) | 18.28 |
| Forward PE | 15.77 |
| P/B (ttm) | 4.26 |
| P/S (ttm) | 2.06 |
| Earnings Date | Nov 3, 2026 |
| Ask | 17.61 |
| Volume | 500,545 |
| Avg. Volume (20D) | 762,427 |
| Open | 13.76 |
| Previous Close | 13.89 |
| Day's Range | 13.71 - 14.39 |
| 52-Week Range | 6.25 - 15.89 |
| Analyst | Strong Buy |
| Price Target | 18 (26.23%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BVS
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, ...
Financial Performance
In 2025, Bioventus's revenue was 568.09M, a decrease of -0.91% compared to the previous year's 573.28M. Earnings were 22.73M, a decrease of -162.93%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for BVS stock is "Strong Buy". The 12-month stock price forecast is 18, which is upside of 26.23% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
